Quotes 5-day view Delayed Nasdaq
09/22/2020
09/23/2020
09/24/2020
09/25/2020
09/28/2020
Date
9.53(c)
9.55(c)
9.69(c)
9.95(c)
9.94(c)
Last
61 008
45 698
39 563
52 734
41 124
Volume
-3.93% +0.21% +1.47% +2.68% -0.10% Change
Sales 2020
19,4 M - -
Net income 2020
-44,5 M - -
Net Debt 2020
-
-
-
P/E ratio 2020
-5,88x
Yield 2020
-
Sales 2021
9,65 M - -
Net income 2021
-62,6 M - -
Net Debt 2021
-
-
-
P/E ratio 2021
-4,88x
Yield 2021
-
Capitalization
255 M 255 M -
Capi. / Sales 2020
13,2x
Capi. / Sales 2021
26,4x
Nbr of Employees
95
Free-Float
72,5%
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is developing products to prevent and cure infectious diseases and cancer. The Company's infectious and oncology product candidates HB-101, HB-201 and HB-202. The infectious disease product candidate, HB-101, is in a randomized, double-blinded Phase II clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation...
Notations Surperformance© of HOOKIPA Pharma Inc.
Trading Rating : Investor Rating :
All news about HOOKIPA PHARMA INC.
News in other languages on HOOKIPA PHARMA INC.
- No features available -
Chart HOOKIPA PHARMA INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends HOOKIPA PHARMA INC.
Short Term Mid-Term Long Term Trends Neutral Neutral Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
4
Average target price
17,75 $
Last Close Price
9,94 $
Spread / Highest target
101%
Spread / Average Target
78,6%
Spread / Lowest Target
50,9%
Please enable JavaScript in your browser's settings to use dynamic charts.
United Kingdom
Canada
France
Deutschland
Schweiz (DE)
Report
